These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1350752)

  • 21. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
    Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
    Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
    Topalian SL; Kasid A; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [LAK sensitivity of human pancreas carcinoma cell lines].
    Sugiura H
    Hokkaido Igaku Zasshi; 1993 Nov; 68(6):921-34. PubMed ID: 7906667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.
    Zambello R; Trentin L; Feruglio C; Bulian P; Masciarelli M; Cipriani A; Agostini C; Semenzato G
    Cancer Res; 1990 Mar; 50(6):1768-73. PubMed ID: 2106387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
    Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mechanisms of enhanced accumulation of transferred LAK cells into tumor sites after chemotherapy].
    Kuramitsu Y
    Hokkaido Igaku Zasshi; 1995 May; 70(3):507-17. PubMed ID: 7590601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ICAM-1 expression by lung cancer cell lines: effects of upregulation by cytokines on the interaction with LAK cells.
    Melis M; Spatafora M; Melodia A; Pace E; Gjomarkaj M; Merendino AM; Bonsignore G
    Eur Respir J; 1996 Sep; 9(9):1831-8. PubMed ID: 8880099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive.
    Lagadec PF; Saraya KA; Balkwill FR
    Int J Cancer; 1991 May; 48(2):311-7. PubMed ID: 1850388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic analysis of K+ ion channel function in lymphokine-activated killer (LAK) cells.
    LeFever A; Liepins A
    Immunopharmacol Immunotoxicol; 1990; 12(1):23-38. PubMed ID: 2351792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactions of lymphokine-activated killer cells and A549 lung carcinoma nodules maintained in three-dimensional culture.
    Gharib M; Tamboise E; Tamboise A; Lièvre N; Vérola O; Beaupain R
    Tumour Biol; 1997; 18(3):135-45. PubMed ID: 9143410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells.
    Futami H; Pilaro AM; Gruys ME; Back TC; Young HA; Wiltrout RH
    Biotherapy; 1991; 3(3):219-32. PubMed ID: 1906724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.
    Kuramitsu Y; Nishibe M; Kobayashi M; Togashi Y; Yuan L; Takizawa M; Okada F; Hosokawa M
    Br J Cancer; 1996 Jul; 74(2):274-9. PubMed ID: 8688335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.
    Haustein M; Ramer R; Linnebacher M; Manda K; Hinz B
    Biochem Pharmacol; 2014 Nov; 92(2):312-25. PubMed ID: 25069049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproliferative cytokines secreted by lymphokine-activated killer cells stimulated with tumor cells.
    Naganuma H; Sasaki A; Nukui H; Tasaka K
    J Neurosurg; 1992 Sep; 77(3):411-6. PubMed ID: 1506888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
    Ozkan A; Ayhan A; Fiskin K
    Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of E-cadherin in drug resistant human breast cancer cells and their sensitivity to lymphokine-activated lymphocytes action.
    Berezhnaya NM; Belova OB; Vinnichuk YD; Tarutinov VI
    Exp Oncol; 2009 Dec; 31(4):242-5. PubMed ID: 20010527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.
    Yanase M; Tsukamoto T; Kumamoto Y; Kato K; Hashimoto Y
    Cancer Immunol Immunother; 1994 Jul; 39(1):22-6. PubMed ID: 7913877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.